Thaçi D, Armstrong A, Lebwohl M, Blauvelt A, Paul C, Puig L, Wang M, Vanvoorden V, Madden C, Wiegratz S, Deherder D, Gordon K. Maintenance of bimekizumab efficacy through 2 years in patients with moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials. J of Skin [Internet]. 2022 Nov. 16 [cited 2024 Jul. 3];6(6):s71. Available from: https://jofskin.org/33014/index.php/skin/article/view/1827